fda compounding semaglutide crackdown 2025 news Drugmakers battle pharmacies over compounded Ozempic and Zepbound : Shots US FDA sends 25 letters

The transition is easy, the experience is measurably better across every factor, and the 5-star independent reviews confirm that the promises made on the website are kept in practice

Retatrutide continues to be evaluated in additional Phase 3 studies across obesity and obesity-related conditions, including knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease (MASLD)

Wegovy (semaglutide injection, Novo Nordisk), Zepbound (tirzepatide injection, Eli Lilly), Saxenda (liraglutide injection, Novo Nordisk), and oral Wegovy (semaglutide tablets, approved December 2025)

If eligible, prescription sent to pharmacy or shipped

Cancer 20 , 629644 (2020)